Novo Nordisk reported promising data on its new weight loss pill, which lowers body weight by up to 13% after 3 months in a Phase 1 clinical trial. The company plans a bigger phase 2 at the end of the year. The rate of weight loss with the experimental pill, amycretin, is more rapid than the popular Wegovy.